---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-017402"
form_type: "8-K"
ticker: "IRIX"
cik: "0001006045"
company_name: "IRIDEX CORP"
filed_at: "2022-08-15T23:59:59+00:00"
generated_at: "2026-06-23T23:40:32.473459+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iridex Q2 revenue $13.8M (+2% YoY); net loss $2.2M; lowers FY22 guidance

## Summary
- Total revenue $13.8M, up 2% YoY; net loss $2.2M ($0.14/sh) vs net income $1.4M ($0.09) prior year due to one-time PPP loan forgiveness.
- Gross margin 45.6% vs 45.5% YoY; operating expenses rose 16% to $8.4M on sales/marketing and R&D investment.
- Cyclo G6 probe sales of 15,000 (-6% YoY); full-year probe guidance cut to 61k-63k from prior 67k-70k.
- Revenue guidance lowered to $56M-58M from $57M-59M, reflecting 4%-8% growth; management cites macro headwinds and COVID surge.
- Received NMPA clearance to market Cyclo G6 platform in China; sold initial systems and conducted clinical launch with 70 physicians.

## SEC filing metadata
- accession: 0000950170-22-017402
- form_type: 8-K
- ticker: IRIX
- cik: 0001006045
- company_name: IRIDEX CORP
- filed_at: 2022-08-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006045/000095017022017402/0000950170-22-017402-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006045/000095017022017402/irix-20220815.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-017402
- JSON: https://secwatch.observer/filing/0000950170-22-017402.json
- Plain text: https://secwatch.observer/filing/0000950170-22-017402.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.